References
- Sabatino M, Kim-Schulz S, Panelli MC et al. Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J. Clin. Oncol.27(16), 2645–2652 (2009).
- Lizee G, Radvanyi LG, Overwijk WW, Hwu P. Improving antitumor immune responses by circumventing immunoregulatory cells and mechanisms. Clin. Cancer Res.12(16), 4794–4803 (2006).
- Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol.17(7), 2105–2116 (1999).
- Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat. Rev.33(5), 484–496 (2007).
- Hamm C, Verma S, Petrella T, Bak K, Charette M. Biochemotherapy for the treatment of metastatic malignant melanoma: a systematic review. Cancer Treat. Rev.34(2), 145–156 (2008).
- Atkins MB, Hsu J, Lee S et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2 and interferon α-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J. Clin. Oncol.10(35), 5748–5754 (2008).
- Gogas H, Ioannovich J, Dafni U et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med.354(7), 709–718 (2006).
- Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol.19(15), 3477–3482 (2001).
- Ohm JE, Gabrilovich DI, Sempowski GD et al. VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood101(12), 4878–4886 (2003).
- De S, Razorenova O, McCabe NP et al. VEGF-integrin interplay controls tumor growth and vascularisation. Proc. Natl Acad. Sci. USA102(21), 7589–7594 (2005).
- Flaherty K, Puzanov I, Sosman Jet al. Phase I study of PL4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol.27(15 Suppl.), (2009) (Abstract 9000).
- Schmidt H, Suciu S, Punt CJ et al. Pretreatment levels of peripheral neutrophils and leukocytes as independent predictors of overall survival in patients with American Joint Committee on Cancer Stage IV Melanoma: results of the EORTC 18951 Biochemotherapy Trial. J. Clin. Oncol.25(12), 1562–1569 (2007).
- Guida M, Riccobon A, Biasco G et al. Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Mel. Res.16(4), 317–323 (2007).
- Bernengo MG, Quaglino P, Cappello N et al. Macrophage-mediated immunostimulation modulates therapeutic efficacy of interleukin-2 based chemoimmunotherapy in advanced metastatic melanoma patients. Mel. Res.10(1), 55–65 (2000).
- Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell. Mol. Ther.7(4), 151–156 (2002).
- Schmidt H, Sorensen BS, Nexo E, von der Maase H. S100β protein I in peripheral blood may predict progressive disease during interleukin-2 based immunotherapy in patients with metastatic melanoma. Mel. Res.14(3), 211–215 (2004).